The OMIX3 platform at the Bio21 Institute is developing a streamlined workflow for mass spectrometry (MS) based clinical multi-omics analyses from a single biological sample. This platform integrates semi-automated sample preparation methodologies with parallel MS analysis utilising a Thermo Orbitrap Astral MS for proteomics and individual Thermo Stellar linear ion trap MS instruments for targeted metabolomics and lipidomics analysis. Two Revvity Janus G3 liquid handling workstations facilitate semi-automated multi-omics sample preparation, including Methyl tertiary butyl ether (MTBE) fractionation of protein, polar metabolites and lipids, and on-deck BCA-based protein concentration estimates and normalisation. The platform incorporates a Revvity BloodIQ workstation, enabling the fractionation of blood samples into plasma and buffy coat components. It has also been optimized for other clinically relevant sample types, including saliva, urine, and stool. OMIX3 platform will support efficient on-site sample handling, storage preparation for biobanking unused samples, and downstream analyses and integration of collected data on the Gen3 data platform. Currently, the platform is evaluating its large-scale clinical multi-omics analysis capacity through its participation in the Health and Vitality in our Community (HViC) study at the University of Melbourne, in collaboration with the Australian Genome Research Facility (AGRF) for genomics analysis, the Murdoch Children's Research Institute (MCRI) for biobanking, and Australian BioCommons for research data infrastructure support. The OMIX3 platform will offer fee-for-service multi-omics solutions, complementing existing high-capacity genomic facilities and addressing specific clinical and translational research requirements across various clinical sample types.